Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06589531

Small Diameter TIPS in Patients with Severe Liver Atrophy and Variceal Bleeding

Portal hypertension is the most common complication in patients with end-stage liver cirrhosis. Portal hypertension-related complications, such as variceal bleeding, often lead to a poor prognosis. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.

In theory, a shunt with a larger diameter can result in better stent patency, but it can also lead to reduced liver function and a higher incidence of hepatic encephalopathy (HE) after the TIPS procedure. Therefore, the choice of covered stent diameter needs to consider the factors of shunt efficacy and postoperative liver function. At present, the diameters of TIPS-dedicated stents are typically either 8 or 10 mm. Whether stents with these two diameters can meet all the requirements of TIPS procedures is currently unknown. Different races, cirrhosis etiologies, and liver volumes may require different TIPS diameters. For example, in China, most cases of liver cirrhosis are caused by hepatitis B, resulting in the patient having a smaller liver volume. Therefore, in most Chinese studies, the diameters of TIPS stents are mainly 8 mm. Previous studies have shown that TIPS with an 8-mm covered stent has a shunt effect similar to that of a 10-mm covered stent; however, the incidence of postoperative HE is significantly reduced with an 8-mm stent (27% vs. 43%)14. Nevertheless, an 8-mm covered TIPS still has a high incidence of HE.

The residual liver volume is small for patients with severe atrophic cirrhosis of the liver, and whether this necessitates a covered TIPS with a smaller diameter requires further study. However, there is still no dedicated TIPS stent that is <8 mm in diameter. In this study, we propose an innovative strategy for the creation of a 6-mm shunt to determine if it can achieve a shunt effect similar to that of an 8-mm covered TIPS and reduce the incidence of HE in patients with severe atrophic liver cirrhosis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed as cirrhosis
  • Previous or present endoscopic diagnosis of esophageal and gastric varices bleeding.
  • Child -Pugh score C (≤13) or MELD≤18.
  • Enhanced image measurement of liver volume ≤1000cm3.
  • Have indications for TIPS treatment.
  • Researchers believe that patients have the ability to comply with the research plan.
  • Sign the informed consent form

Exclusion criteria

  • Malignant tumor (including hepatocellular carcinoma) or other diseases that will shorten the life span of patients.
  • Cavernous portal vein
  • Non-cirrhotic portal hypertension (Budd-Chiari syndrome, extrahepatic portal vein obstruction, idiopathic portal hypertension, etc.)
  • Spontaneous dominant hepatic encephalopathy 5 congestive heart failure or severe valvular heart failure
  • Uncontrollable systemic infection or inflammation 7. Severe pulmonary hypertension 8. Severe renal insufficiency (except hepatogenic renal insufficiency) 9. Rapidly progressing liver failure 10. Contrast agent allergy 11. History of liver transplantation or allogeneic organ transplantation 12. Have a history of TIPS or shunt operation. 13. Pregnancy or lactation 14. Poor compliance 15. Participate in another clinical study.

Treatment and study plan

During TIPS operation, shunt diameter or diameter of covered stent

Device

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.

Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore & Associates) to create a final 6-mm shunt.

Primary outcomes

  1. The 1- year rates of rebleeding

    Time frame: From receiving TIPS to one year after the end of treatment

  2. The 2- year rates of rebleeding

    Time frame: From receiving TIPS to two year after the end of treatment

Secondary outcomes

  1. The 1- year stent patency rates

    Time frame: From receiving TIPS to 1 year after the end of treatment

    During the follow-up, there was no thrombosis in the stent and complications related to portal hypertension caused by stent occlusion.

  2. The 2- year stent patency rates

    Time frame: From receiving TIPS to 2 year after the end of treatment

    During the follow-up, there was no thrombosis in the stent and complications related to portal hypertension caused by stent occlusion.

  3. The 1-year cumulative incidences of overt HE

    Time frame: From receiving TIPS to 1 year after the end of treatment

    HE greater than or equal to 2

  4. The 2-year cumulative incidences of overt HE

    Time frame: From receiving TIPS to 2 year after the end of treatment

    HE greater than or equal to 2

Study contacts

Contact information is provided by the study sponsor or research team.

Huzheng Yan, doctor

CONTACT

[email protected]

8613610176039 ext. 131610176039

Mingsheng Huang, doctor

CONTACT

[email protected]

+8613600004855

Sponsors and collaborators

Lead sponsor

Huang Mingsheng

Other

Registry information

Official study title

6 Mm Shunt Transjugular Intrahepatic Portosystemic Shunt in Patients with Severe Liver Atrophy and Variceal Bleeding:A Prospective Single-center Randomized Controlled Study

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Sep 19, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.